The goal of Stealth BioTherapeutic’s Mitochondrial Carrier Technology (MCT) platform is to utilize the unique ability of our proprietary compounds to deliver biologically-active cargo to mitochondria.
While in the investigational stage, our data confirm the ability of our carrier compounds to direct biologically active cargo to mitochondria that would usually be distributed to other subcellular locations. This approach shows promise for mitochondrial localization of small molecules, and may also have the potential to deliver peptides, proteins and oligonucleotides. Targeted delivery of mitochondrial medicine is likely to lead to more efficient therapies, opening possibilities to lower efficacious dosing levels and minimize off-target toxicity.
For more information on Stealth BioTherapeutic’s MCT Program, please contact MCTProgram@StealthBT.com.